Table 4.
Pharmacokinetics properties of BEA.
| Absorption | |
|---|---|
| Water solubility (log mol/L) | −2.984 |
| Caco2 permeability (log Papp in 10-6 cm/s) | 0.919 |
| Intestinal absorption (human) (% Absorbed) | 63.474 |
| Skin Permeability (log Kp) | −2.735 |
| P-glycoprotein substrate | Yes |
| P-glycoprotein I inhibitor | Yes |
| P-glycoprotein II inhibitor | Yes |
|
Distribution | |
| VDss (human) (log L/kg) | −0.402 |
| Fraction unbound (human) (Fu) | 0.121 |
| BBB permeability (log BB) | −0.831 |
| CNS permeability (log PS) | −2.408 |
|
Metabolism | |
| CYP2D6 substrate | No |
| CYP3A4 substrate | Yes |
| CYP1A2 inhibitor | No |
| CYP2C19 inhibitor | No |
| CYP2C9 inhibitor | No |
| CYP2D6 inhibitor | No |
| CYP3A4 inhibitor | Yes |
|
Excretion | |
| Total Clearance (log ml/min/kg) | 0.981 |
| Renal OCT2 substrate | No |
|
Toxicity | |
| AMES toxicity | No |
| Acute Oral Toxicity Class | III |
| Skin Sensitization | No |
| Hepatotoxicity | Yes |
| Carcinogenicity | No |